Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Pre-IC: Sintilimab + Chemo for Stage IIIA/IIIB NSCLC
NCT04326153Phase 2Active, not recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Mar 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by The First Hospital of Jilin University. Started Mar 2020; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04326153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326153.